Similar articles

• Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.

  Ochoa AC, Hasz DE, Rezonzew R, Anderson PM, Bach FH. Ochoa AC, et al. Cancer Res. 1989 Feb 15;49(4):963-8. Cancer Res. 1989. PMID: 2521457
• A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.

  Shimizu K, Park K, Yamada M, Tarura K, Matsui Y, Hayakawa T. Shimizu K, et al. J Clin Lab Immunol. 1990 May;32(1):41-7. J Clin Lab Immunol. 1990. PMID: 1967036
• Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

  Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Ochoa AC, et al. J Immunol. 1987 Apr 15;138(8):2728-33. J Immunol. 1987. PMID: 2435804
• Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality.

  Grimm EA. Grimm EA. Biochim Biophys Acta. 1986 Dec 17;865(3):267-79. doi: 10.1016/0304-419x(86)90017-x. Biochim Biophys Acta. 1986. PMID: 3539198 Review.
• Cell surface recognition determinants involved in triggering the lymphokine activated killer cell phenomenon: enhanced killing of modified "anti-self" targets by varying LAK culture conditions.

  Finkelstein DM, Miller RG. Finkelstein DM, et al. J Otolaryngol. 1990 Oct;19(5):294-8. J Otolaryngol. 1990. PMID: 2262945 Review.